Literature DB >> 16681817

A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis.

Shinichi Watanabe1, Hisashi Takahashi, Takeji Nishikawa, Iwao Takiuchi, Nobuhiko Higashi, Katsutaro Nishimoto, Saburo Kagawa, Hideyo Yamaguchi, Hideoki Ogawa.   

Abstract

The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of tinea pedis (interdigital-type and plantar-type). A multi-clinic, randomised single-blind, parallel group study with 34 hospitals and 11 clinics formed the study design. Five hundred and eleven patients with mycologically confirmed tinea pedis were included. Of the 489 evaluable patients, 247 were randomised to luliconazole, and 242 to bifonazole. Luliconazole 1% cream applied once a day for 2 weeks, followed by a placebo cream for 2 weeks, thereafter. Bifonazole 1% cream applied once a day for 4 weeks. Mycological effect (negative result on microscopy) and improvement of skin lesions were measured at weeks 1, 2, 3 and 4. Safety frequency and severity of adverse reactions were also measured. The improvement of skin lesions after 4 weeks was comparably good with rates of 91.5% vs. 91.7% (luliconazole vs. bifonazole). The mycological effect was characterised by high negative rates of 76.1% vs. 75.9% (luliconazole vs. bifonazole). The progression of tinea-related signs and symptom scores differed insignificantly between evaluated luliconazole and bifonazole treatment groups comprising a total of 500 patients. Both substances appeared to be comparably safe and well-tolerated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681817     DOI: 10.1111/j.1439-0507.2006.01218.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  6 in total

1.  Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis.

Authors:  Hiroyasu Koga; Yasuko Nanjoh; Hideo Kaneda; Hideyo Yamaguchi; Ryoji Tsuboi
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 2.  The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options.

Authors:  Shyam B Verma; Saumya Panda; Pietro Nenoff; Archana Singal; Shivprakash M Rudramurthy; Silke Uhrlass; Anupam Das; Kavita Bisherwal; Dipika Shaw; Resham Vasani
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 [SEASON]       Impact factor: 2.545

Review 3.  Animal model of dermatophytosis.

Authors:  Tsuyoshi Shimamura; Nobuo Kubota; Kazutoshi Shibuya
Journal:  J Biomed Biotechnol       Date:  2012-04-29

4.  Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses: A prospective, randomized, open-label study.

Authors:  Ganesh N Dakhale; Ashish V Gupta; Jayesh I Mukhi; Mrunalini V Kalikar
Journal:  Perspect Clin Res       Date:  2021-01-08

Review 5.  Luliconazole for the treatment of fungal infections: an evidence-based review.

Authors:  Deepshikha Khanna; Subhash Bharti
Journal:  Core Evid       Date:  2014-09-24

Review 6.  A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections.

Authors:  Aditya K Gupta; Deanne Daigle
Journal:  Infect Drug Resist       Date:  2016-01-18       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.